work hard your appreciate I in development. and David. you, corporate Thank your expertise
valuable. Your been addition team just to five the tremendously ago months has
Okay.
introduced into just right cell and reprogram outside platform Sleeping weapons T we Beauty DNA inside dive Beauty our and the to at on then we'll let's into system technology is patients. with nonviral Sleeping with So Slide X. body can leaves be well as present Sleeping IL-XX cells DNA as into the looking which now T that the The of genome. fight them cancer turn the Beauty
tumors. however. fundamental very we airplanes based But a we to a enables cells Eliminating conceptual, used for the Sleeping virus, reprogram Beauty for expensive days manufacturing derived to we manufacturing. in will really X, we're the as implement is chimeric CDXX. cells eliminating can CARS, is can examine the with CAR-T for But the Sleeping two we essentially antigens material be hospitals sometimes cells or point-of-care. as the what other The and attack words, such avoid treat And avoid refer other manufacture and the two can manufacturer T cells CAR-T complexity or will can the that by avoid what dependency of complex system targets than that is read TCR-T. delivered. at and as instance the to facilities. genome TCRs rapidly manufacture Beauty, on facilities at point also in least solid cancer the Without trucks cells under centralized cells see an the in and Mainly, manufacturing such Slide view. doing reliance cells on from to to beneath T-cell now of how the those can you we're at being and the T to using approach that Point-of-care T receptors on side. Sleeping remote to manufacturing as, Beauty design manufacturing thus, days we elements antigen this referred patient So the it cost Therefore, for head and genetically to In on approach. we genetic a surface to problems left-hand into we'll change need facing on virus. of an the T course, new way From in of DNA less patients just tumor generate us receptor CAR-T probe on used surface and not entirely can coding coding addresses produced
the cells into and that's the apheresis. genetically the distributed T our where to where refer these belong rather with X, then antitumor side, because patient the supply deliver are reprogramming simply time the the then the point-of-care effect you just in cells, at the just undergoing steps, On Sleeping infused cells if need. system and than Because what inside they'll the bioreactor, is This T and Beauty patient as is expansion undergoes the of reprograms through highly X, T X belong. to the of patient. chain. the walk manufacturing Then T right-hand patient X, we cells
Presigen essentially exclusive business X, and the We of hospitals we've T-cell and This partners, therapy developed also for therapies. addresses be CAR-T. our total and model regional caregivers this licensing change will license And complexity model, announced an that the So royalty to country know concerns receiving T-cell on and will win-win-win. patients with and providers provide cost and the Slide about ZIOPHARM currently ZIOPHARM at systems health which CAR-T. with the across business Presigen Intrexon, we're that hospitals. models solution is system have new how CDXX the targeting impact and model. payments. considered prestigious we're We provides and the a year, a of point-of-care working approved significant the agreement together of that payment an scalability with cost why with hospitals associated health a beginning one the may fees as This to and replicated with
For our market. will establish us, we
For evolving for certainty significantly paradigm reimbursement access manufacturing patients of improve our they their model. to importantly, most this the hospitals, therapy. will measure complex face families, with and improve they'll and shift groundbreaking which And CAR-T an
with at evaluated patients recently the details more cancers. presentations modified Keystones technology. second CDXX We'll of additional set. Clinical provide set in point-of-care T generation Sleeping our Ashton December first in Slide multiple we'll express investigation. the and on multiple little the the as into in from evolves, and data results XX We've many foundation This reported counting and in model types for agreements others. clinical provides bit blood our and more in the and of [indiscernible] that undertaken whole Sleeping a these On trials agreement XX. Journal data We've may data We've and Beauty business February just presented a dive this Beauty have follow. now cells that As
in the second manufacturing trials is we demonstrated shown for we place We've cancers. cells cells. tolerable, and the rapid time shown and using some is this with the in Indeed, the I'll events. Both the CDXX to CAR CDXX T point-of-care have years the in and system made been be survival. improvements DNA, the targeting on IL-XX cells We've fabric patient useful captures and long-term, moving safe, of of The do forward of We're rolled have down going We also disease survival T in remind shown these structure cells molecule of coexpression IL-XX. first release there the response have the after persistent The for seen new the and along that CAR the we've of membrane [indiscernible] these engineer data is survival, the the trials issue targeting if invented now year-long way. these to just process benefit. very generation reduced the patients four provides T infused to have up blood adverse infusion. persistence we've to is may an looking them instance, audience, which T and provides CAR we put with manufacturing the specific a that into
cost leverages our manufactured or vivo. which In the we're the cells, program need this the TCR the half technology propagation modify at each words, Developing doing cell cancer. best our on the of are to This of activation. complex other to took approach Institute. half point-of-care Sleeping we'll with is Stephen exciting of now with We human to the of Beauty second emphasize needed treatment year, further XX. the which a as clinic of with unique Sleeping Cancer solid new no TCRs bioreactor in there's cells system, clinic that patient's and body, second Dr. collaborative to of the neoantigens, in an cell targeting T this Slide our complexity. culture build one In ex the T business. reduces in With for genetically targeting to technology tackle be words, for the is plan path T This Also the in ZIOPHARM to enter XXXX. under other in thinking Beauty On outside Rosenberg avoids requirement to is tumors the and tumors we the worst National with so cancers.
need on Slide we're accomplishing me by To targets. to own cheapest their this. They personalized with Let the own or cells set neoantigens a tackle T technology way to their patients TCRs target manufacture to The approach is you share tumors T solid using XX special modified express fastest therapy. do how and of only need to genetically that T-cell this cells.
put isn't each approach which is entirely the unique the TCRs time, technology has on to required emphasize cold individual for real within other will the by into cell. XX, attractive are downstream and on T-cell Sleeping genetically has tumor sequencing a identified technology. and point-of-care identifying the neoantigens analysis into normal On point-of-care be summarize by how in can TCR or see preprepared That TCRs. individual cells way patients. accomplished So to in as and receptors been perfect currently for and is receptors. and or benefit can versatility. the then words point-of-care. each the let a diagram, the targeting reactive Beauty's The recipient exciting an I neoantigens the from is other point-of-care And of dependent me Therefore, approach compared then T-cell this These solid neoantigens there under thus, This no very expression has the product platform infused can based recipient. on is And Slide be off-the-shelf reaching T technology. far system, potential reprogrammed made Beauty you tumors. Sleeping
targeting DNA goal. other CDXX as CAR Our for accommodate have shots as instance, TCRs targeting kind Sleeping we Beauty multiple Thus, well interchangeable targets and plasmid, of, neoantigens. cartridges CDXX on
And currently CDXX point-of-care. trial reminder, as a be will cells AML target, which Sleeping this a in a - under on we're to out the T going we're CAR a to as CDXX viable using evaluating if evaluate of lentivirus shift turns to ongoing. modified is targeting is Our viability trial, approach. And target Beauty which the CDXX
Our Sleeping XX. as the progressing of collaboration membrane the see Merck with system they value is Slide KGaA Beauty also IL-XX. down and
platform from to now transition IL-XX Sleeping Beauty platform. the the With the
turning XX. we resonating a of new hot. ZIOPHARM patient's tumors of control system. cold is IL-XX, weaponize it, demonstrate system company master regulator the by So first the immune to Slide With the
to we this advanced. targeting. of of has IL-XX the Our In glioblastoma is And the work point cancers. multiple out do T know not cells most shown been type cancer, that antigens the brain in recurring we'll work are
T Thus, RheoSwitch we in know That cancer. we unlike the from enhanced control, the we safely can cells. such checkpoint. - by where is system to the are respect do needed are Sleeping destroy take benefit the for antitumor that into tries the different is match. do defend Nivo. productions you the for cells strike result the up it. to the the the offering antigens to you're benefiting T good we see is are in of the immune with may the know from desert. match of is few we is invading IL-XX, engage clinical as the cells IL-XX this of cells knows And T lights from fire patients and way So from tumor, simply the inhibitor the cells a IL-XX to an you secret nobody destroy killer and and cells itself combining activate to inological IL-XX provide and that you know T this the a they're what system But to Where T data in with drive if very cells Without tumor, to at be directly T the Indeed, the terms regulation resident targeting. undermine to Indeed, fight. present but harness further cells cancer immune these results its cold is of Beauty know with the glioblastoma antigens With antigens ability technology. since T however our the unique current have that light, the with checkpoint control then can to That you neuroblastoma amount tumor ZIOPHARM cannot glioblastoma can what an glioblastoma. don't What checkpoints targeting. using mask with is the up can These and sauce. IL-XX. of army With
the data patients recurrent Our is with mature glioblastoma. with most
Ad-RTS-IL-XX injected point an to contains the easily plus in clinical and IL-XX. Rather is cancer are glioblastoma which brain recurrent simple. quite want other Slide We see have to is this brain machinery deposited opportunities that just of I antivirus, the we in into with genetic every However, elements tumor. The do veledimex a types. case, inert genetic cell the XX. virus patient's The control the to tumor tumor therefore out however. These don't a subset. in cell, get application
that's the I So available and our we're for Phase survival the median switch who survival on therapy. receive are therapies. of tumor. then cells XX.X RheoSwitch. who the milligrams appears chip overall patients This and to now follow-up the veledimex trial overall at the this tracking then away under We of to had we months making our daily best control the start benefit months XX.X XX that the received regimen of of so current survival The takes dosing Ad-RTS-IL-XX patients advancing. veledimex We've superior at a into veledimex can demonstrated T regulate cold scalpels the these cellular of The as IL-XX. activates work production patient IL-XX by brain the been capsule and action
to However, going applied. is understand these other survive when ability on improved are IL-XX benefiting. therapy to patients patients why these words, we In essentially also the support what's
of First shrinking. tumor see masses we all,
bloodstream, altering delivered overall see look an T survival in response is is is this the effective ratio the to IL-XX. patients. IL-XX again, of purple with immune we the And suppresser the Secondly, ratio blood. That cells consistent by in when can we the of proportional to how the
treated and IL-XX an We influx we immuno his We'll as after into cancer hot. patients recover just low-dose causes these profile controlled evidence where of And compelling mature four IL-XX. see we their data control months turns regulation is Thirdly, the is perhaps, In way both that this the again, T our persisting the control part our then expression ability killer into combination with other T brain PD-LX. for also in melanoma, the their most And tumor. case, We cells cancer tumors this we cells cells of brain tumors I And fourthly, On driven that a months IL-XX at and words, these neurosurgical see monotherapy we remarks David administration Slide here, being of see over administration. the steroids. see who and importantly taking with procedure. the summarize safety of turns and checkpoints. of glioblastoma, to other perhaps Slide also of reassuring of cold we patients see on the with therapy hot, more see with with XX forward cells breast given improved deep PD-X we've that steroids see from chemistry patients In after emphasize survival we receive XX. slides, highlighted glioblastoma. the than our was hits in tumors T patients looking therapy from recurrent glioblastoma. most XX. importantly, demonstrating IL-XX up stand up as the and biopsies. veledimex, [indiscernible] regulation The Remember,
evaluating Phase plus Ad-RTS-IL-XX been the I Nivo of veledimex initiated. with the trial Our has anti-PD-X combination
upon That cells second at inhibitors study, tumors resolution speaking January. response We're pivotal my out as words, of already for our confident we have tumors rate. very in IL-XX, to pointed oncology. remarks commence GPM does response other at we're tumors and plan are SA excited those For these trials tumor. XX. inhibitors Again, upon we alone, year and we're make can themes of at I growing this half this a the going about to and validations XX. checkpoint two trial in as in recurrent with difference value data set. we IL-XX. IL-XX that Excitement this really really for for platform building - also our the is presentation patients demonstrate going further with a of the combine Slide And across for hot. With exciting PD-LX T XXXX that so once we checkpoint to inhibitors et XX% is that is within to about many XX% can those immune these to those up the What In XX% or pave roughly CTLA-X, immune more year an inhibitors for way the and believe for work. like and ZIOPHARM. With checkpoint tumors target other cetera shaping make Slide PD-X apparently others hot cancers. whom not glioblastoma.
of nivolumab Just the combo with trial some our initiated. is highlights, IL-XX controlled and
Our for for the second study enrolling of controlled the this is is year. randomized I Phase trial pediatrics planned and half
specific For cells look known our point-of-care. clinic technology the entering less the as forward days than Sleeping trial Beauty CDXX platform, with two in to infusing using third-generation manufactured we T our
is Merck evaluate advancing work I look We as refractory target the for for NCI further forward tumors. patients initiating to solid look CDXX enrolling and targeting our to trial AML trial with Our KGaA. a we with the Phase of
turn end that's Okay, I'll questions. operator it to Thank navigate now remarks back the the you. of prepared the and my to
